Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

Johnson & Johnson (NYSE:JNJ) is a global healthcare leader with a diverse portfolio across pharmaceuticals, medical devices, ...

A panelist discusses how a large propensity score–matched analysis of 1300 patients aged 60-75 found similar all-cause ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences ...

The therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50% ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat ...